Introduction Vaginal lactobacilli are associated with favourable sexual health outcomes and acidify the vagina to pH <4.0 by producing 0.3-1% D and L isomers of lactic acid (LA). Epithelial cells that line the vagina and cervix have barrier and immune functions in the lower female reproductive tract (FRT). Here we investigate the immune modulatory effects of L-LA on lower FRT epithelial cells that might influence HIV susceptibility. Methods The effect of apically applied L-LA (0.3% w/w, pH3.9) was assessed on vaginal (VK2), endocervical (End), ectocervical (Ect) epithelial cell lines and primary ectocervical cells grown in transwells. Elicited immune mediators were quantified following apical stimulation with toll-like receptor (TLR) agonists ± L-LA by flow cytometry and luminex-based assays. Background A randomised trial of monthly periodic presumptive treatment (PPT) with intravaginal metronidazole 750 mg plus miconazole 200 mg reduced bacterial vaginosis (BV) by 35% compared to placebo. We further assessed the effect of the intervention on detection of select bacterial species in the vaginal microbiome. Methods HIV-uninfected, non-pregnant women aged 18-45 years from the US and Kenya were randomised to receive PPT or matching placebo for 5 consecutive nights each month for 12 months. Vaginal fluid specimens were collected every other month using Dacron swabs and tested using species-specific quantitative PCR assays that target the 16S rRNA gene. Relative risks [RR] were generated using generalised estimating equations with a log link and exchangeable correlation structure to separately assess the effect of the intervention on species detection. Results Of 234 women enrolled, 221 (94%) had specimens for analysis (PPT n = 110; placebo n = 111). The proportion of follow-up visits with individual species detected was lower in the PPT arm versus placebo for: BVAB1 (13.8% vs. 23 ; p = 0.07). However, these increases were not statistically significant. The prevalence of Gardnerella vaginalis and L. iners during follow-up was high (90% and 91%, respectively) and did not differ by arm. Conclusions Use of monthly PPT for one year significantly reduced BV prevalence as well as colonisation with a number of bacterial species strongly associated with BV.
Introduction Vaginal lactobacilli are associated with favourable sexual health outcomes and acidify the vagina to pH <4.0 by producing 0.3-1% D and L isomers of lactic acid (LA). Epithelial cells that line the vagina and cervix have barrier and immune functions in the lower female reproductive tract (FRT). Here we investigate the immune modulatory effects of L-LA on lower FRT epithelial cells that might influence HIV susceptibility. Methods The effect of apically applied L-LA (0.3% w/w, pH3.9) was assessed on vaginal (VK2), endocervical (End), ectocervical (Ect) epithelial cell lines and primary ectocervical cells grown in transwells. Elicited immune mediators were quantified following apical stimulation with toll-like receptor (TLR) agonists ± L-LA by flow cytometry and luminex-based assays. Results L-LA had little impact on FRT epithelial cell viability. Stimulation of FRT epithelial cell lines with the TLR3-agonist poly (I:C) (PIC) induced high-levels of pro-inflammatory cytokines (IL-6/IL-8), and their variable induction with TLR agonists Pam (3) CSK(4) (TLR1/2) and lipopolysaccharide (TLR4). Conversely, L-LA treatment significantly reduced PIC-induced IL-6 (~30-fold) and IL-8 (3-4.5-fold, p£0.03) secretion, compared to PIC-only treated FRT epithelial cell lines. Irrespective of TLR stimulation, L-LA elicited a 4-11-fold (p < 0.01) increase in the anti-inflammatory cytokine IL-1RA in FRT epithelial cell lines. Neither 0.3% L-LA at neutral pH nor acidity alone (HCl, pH 3.9) elicited the abovementioned effects indicating that immune modulation is mediated by the protonated form of L-LA and is not due to low pH. L-LA also reduced PIC-induced secretion of RANTES and MIP3a in all cells, associated with recruitment of HIV target cells to the mucosa. Similar anti-inflammatory effects of L-LA were observed in primary ectocervical cells. Conclusion L-LA found in lactobacillus-dominated vaginal microbiota elicits an anti-inflammatory effect on lower FRT epithelial cells and dampens inflammation induced by microbial TLR agonists suggesting a role in mitigating inflammationinduced HIV susceptibility at the vaginal mucosa. Disclosure of interest statement This study was funded by NHMRC Project APP1088564. No pharmaceutical grants were received in the development of this study. Background A randomised trial of monthly periodic presumptive treatment (PPT) with intravaginal metronidazole 750 mg plus miconazole 200 mg reduced bacterial vaginosis (BV) by 35% compared to placebo. We further assessed the effect of the intervention on detection of select bacterial species in the vaginal microbiome. Methods HIV-uninfected, non-pregnant women aged 18-45 years from the US and Kenya were randomised to receive PPT or matching placebo for 5 consecutive nights each month for 12 months. Vaginal fluid specimens were collected every other month using Dacron swabs and tested using species-specific quantitative PCR assays that target the 16S rRNA gene. Relative risks [RR] were generated using generalised estimating equations with a log link and exchangeable correlation structure to separately assess the effect of the intervention on species detection. Results Of 234 women enrolled, 221 (94%) had specimens for analysis (PPT n = 110; placebo n = 111). ; p = 0.07). However, these increases were not statistically significant. The prevalence of Gardnerella vaginalis and L. iners during follow-up was high (90% and 91%, respectively) and did not differ by arm. Conclusions Use of monthly PPT for one year significantly reduced BV prevalence as well as colonisation with a number of bacterial species strongly associated with BV. The role of PPT to improve vaginal health should be considered. Disclosure of interest statement R. S. M. has received honoraria for invited lectures and consulting as well as donated study product for this trial from Embil Pharmaceutical Company. R. S. M. currently receives research funding from Hologic/Gen-Probe. J. E. B. received honoraria from Symbiomix, Inc for consulting and donated reagents from Hologic/Gen-Probe. J. S. has received consultancy payments from Akesis, Hologic, Symbiomix, and Starpharma, and has grants/pending grants from Akesis, BD Diagnostic, Hologic, Cepheid, Quidel, Symbiomix, Starpharma, and Viamet. All other authors declare that they do not have a commercial or other association that might pose a conflict of interest. Introduction IL-36g (also designated as IL-1F9) has been recently identified and belongs to the IL-1 family of cytokines. Despite expression of IL-36g at other mucosal sites, it has not previously been reported in the vaginal or cervical epithelium. Overall, there is a paucity of information regarding the induction and physiological function of IL-36g.
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P06.12 HUMAN IL-36 GAMMA AS AN INDICATOR OF VAGINAL INFECTION AND PROMOTER OF MUCOSAL INFLAMMATION
Methods Utilising our human 3-D vaginal EC model, that more accurately recapitulates in vivo human vaginal tissue, we tested the hypothesis that IL-36g induction in the vaginal epithelium is microbe-dependent by testing a panel of STI microbes and microbial products. To further investigate the induction and regulation of IL-36g, 3-D vaginal EC were treated with poly (I:C), flagellin or FSL-1 for 24 h. Human 3-D cells were analysed by real-time qPCR analysis. Cell pellets and culture supernatants were also collected and analysed by IL-36g ELISA, Western blot and cytometric bead array.
Results Following exposure to STI pathogens (herpes simplex virus and bacterial vaginosis (BV)-associated bacteria) and specific microbial products, IL-36g expression was significantly increased relative to untreated and Lactobacilli spp. bacteria in the vaginal EC model. All microbial products tested significantly (p < 0.05) induced expression of IL-36g in a dose-and TLRdependent manner. Treatment with IL-36g significantly (p < 0.05) induced proinflammatory cytokines and antimicrobial peptides (AMP). Recombinant IL-36g treatment resulted in cytokine and AMP production, thereby promoting inflammation in the local microenvironment. Conclusion We show that human 3-D vaginal EC express IL-36g and this cytokine is elicited in a microbe-dependent manner at this mucosal site. Furthermore, we demonstrate that IL-36g is an important driver for epithelial activation and inflammation following infection with STI-related pathogens and BV-associated bacteria, as such this novel cytokine may play an important role in host defense in the vaginal epithelium. Disclosure of interest statement No pharmaceutical grants were received in the development of this study. 
